Ultimovacs - Data continue to impress in Phase I UV1 study

03.09.21 08:18
Edison Investment Research

The highlight of Ultimovacs’ Q221 analyst call was the presentation of data from the second cohort of patients enrolled in the Phase I trial in melanoma (UV1 plus Keytruda). This is the first Ultimovacs’ trial in the US and the main goals are to gather initial insights on how UV1 combines with a checkpoint inhibitor (CPI) and to test different doses of adjuvant. Ultimovacs has an ongoing Phase II trial in melanoma with a different combination of CPIs. The Phase I trial was therefore not the primary driver in Ultimovacs’ investment case until positive first data were presented at this year’s ASCO conference in June, which came as a surprise. With the caveat that these are still early-stage results from a Phase I trial, the second set of data announced in August 2021 showed a very similar response, which helps maintain our high expectations Our valuation is increased to NOK4.08bn or NOK128/sh (versus NOK114/sh previously).

hier klicken zur Chartansicht

Aktuelle Kursinformationen mehr >
Kurs Vortag Veränderung Datum/Zeit
12,00 € 11,88 € 0,12 € +1,01% 17.09./20:00
ISIN WKN Jahreshoch Jahrestief
NO0010851603 A2PKSD 12,00 € 4,14 €
Handelsplatz Letzter Veränderung  Zeit
Frankfurt 12,00 € +1,01%  17.09.21
  = Realtime
Aktien des Tages

Jetzt für den kostenfreien Newsletter "Aktien des Tages" anmelden und keinen Artikel unseres exklusiven Labels AC Research mehr verpassen.

Das Abonnement kann jederzeit wieder beendet werden.

Meistgelesene Artikel
Aktuelle Diskussionen
Antw. Thema Zeit
4 https://ultimovacs.com/about-ulti. 16.05.21
RSS Feeds

Bitte warten...